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ABSTRACT
Allogeneic stem cell transplantation following myeloablative conditioning in relapsed and refractory Hodgkin
lymphoma (HL) has been associated with substantial transplant-related morbidity and mortality, as well as high
relapse rates. Despite these problems, a minority of patients have experienced long-term remissions and
presumably cure. As in other hematologic malignancies, reduced intensity conditioning (RIC) has now been
introduced as an alternative approach. The published experience with RIC in HL patients is reviewed. While
early transplant-related morbidity and mortality seem markedly reduced and preliminary data on patient
outcome look promising, this remains a challenging area and additional work will be needed to clearly define
the role of RIC in relapsed and refractory HL.
© 2006 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
Allogeneic stem cell transplantation (allo-SCT)
ith reduced intensity conditioning (RIC), as opposed
o conventional myeloablative conditioning, has been
aining increasing acceptance in the management of a
ariety of hematologic malignancies [1,2]. Because the
ole of allo-SCT in relapsed/refractory Hodgkin lym-
homa (HL) has been controversial, it is not surpris-
ng that this area has not received the same level of
ttention as other hematologic disorders. As a conse-
uence, published reports remain somewhat sketchy,
ut interest seems to be growing, partly because the
reliminary data appear very encouraging. This re-
iew brieﬂy summarizes the current status of the ﬁeld
rom a clinical, evidence-based perspective.
LLO-SCT WITH MYELOABLATIVE CONDITIONING:
UBLISHED RESULTS
The role of allo-SCT in the management of re-
apsed/refractory HL has historically been controver-
ial. Published data remain largely limited to registry
eries and retrospective historical data from large
ransplantation centers [3-7] and are summarized in t
B&MTable 1. The vast majority of these patients received
ransplants from related donors. The consistent pat-
ern that emerges from these reports paints a disap-
ointing picture. It is a pattern of high transplant-
elated mortality (TRM) and relapse rates, with only
minority of patients (15% to 20%) achieving long-
erm remissions and possibly cure. This poor outcome
s likely to reﬂect the nature and poor prognosis of the
atients undergoing transplantation, with the vast ma-
ority being extensively pretreated with chemotherapy
nd radiation and having advanced, chemoresistant, or
ruly refractory disease.
Whether a graft-versus-HL effect exists in this con-
ext is uncertain and the results of at least some of these
tudies have raised this possibility. Milpied et al [5] (and
ubsequently Peniket et al [7]) showed such an effect
ith grade 2 acute graft-versus-host disease (GVHD)
5,7]. Anderson et al [4] reported a lower relapse rate in
atients with HL who received an allo-SCT compared
ith recipients of an autologous SCT, and Akpek et al
6] reported a trend toward lower relapse rates in pa-
ients with HL who underwent transplantation while in
hemosensitive relapse and patients who developed
VHD. Even if present, it could have been obscured byhe substantial early and late TRMs. Nevertheless, be-
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6ause of these data, clinicians have frequently been re-
uctant to consider this as a viable option except in
elected patients with suitable donors (eg, extensive mar-
ow involvement, inability to collect stem cells).
It would be easy to argue that these largely historical
ata (most patients underwent transplantation from the
970s to the early 1990s; Table 1) no longer reﬂect
urrent clinical practice, which is characterized by im-
roved supportive care and GVHD management. The
ost recent reference seems to paint a somewhat rosier
icture, with improved TRM, progression-free survival,
nd overall survival [6]. Conversely, patient selection
ay have contributed to better patient outcome, and a
umulative TRM of 43% remains very problematic.
LLO-SCT WITH RIC: PUBLISHED RESULTS
In view of the high TRM after myeloablative allo-
CT in HL, these patients seem to be particularly well
able 1. Published Results for Allogeneic Stem Cell Transplantation wi
odgkin Disease*
Reference Patients, n
Period
Covered TRM P
BMTR [3] 100 1982-1994 13% (day 30)
61% (3 y)
BMT [5] 45 1983-1993 31% (day 100)
48% (4 y)
HCRC [4]† 53 1970-1991 58% (4 y)
HOC [6] 53 1985-1998 32% (100 d)
43% (total)
BMT [7]‡ 167 1982-1998 52% (4 y)
IBMTR indicates International Bone Marrow Transplant Regis
FHCRC, Fred Hutchinson Cancer Research Center; JHOC, Jo
progression-free survival; OS, overall survival.
Includes 6 patients who underwent allograting from a mismatche
Includes 5 patients who underwent allograting from unrelated do
able 2. Published Results for Allogeneic Stem Cell Transplantation wi
ymphoma*
Reference
Patients,
n Donor Type Conditioning R
BMT [9] 311 MRD (n  211)
MUD (n  61)
Other (n  39)
Miscellaneous (p
fludarabine-al
agents)
KCG [8] 49 MRD (n  31)
MUD (n  18)
Fludarabine-me
alemtuzumab
PCP [13] 40 MRD (n  37)
MUD (n  2)
Other (n  1)
Fludarabine-me
DAH [14] 40 MRD (n  20)
MUD (n  20)
Fludarabine/
cyclophospham
fludarabine/m
HCRC and
others [11]
27 MRD (n  18)
MUD (n  9)
Low-dose
TBI/fludarabin
EBMT indicates European Group for Blood and Marrow Transpl
Prospective Cooperative Protocol; MDAH, MD Anderson Hosp
related donor; MUD, matched unrelated donor; DLI, donor le
PFS, progression-free survival; OS, overall survival; TBI, total body ir
00uited to an RIC approach. The underlying assump-
ion is that patients will tolerate the procedure much
etter, which may allow them ultimately to beneﬁt
rom a graft-versus-HL effect. Currently available
ata on RIC allo-SCT in relapsed/refractory HL are
ummarized in Table 2. If one excludes case reports
nd studies with a very small sample size, they come
rimarily from the 5 sources listed. It should be em-
hasized that these reports are quite difﬁcult to interpret
nd compare due to a variety of factors (such as patient
nd preparative regimen heterogeneity, short follow-up,
ifferent GVHD prophylaxis regimens, etc). Despite
hese problems, several tentative conclusions can be
rawn.
First, the common denominator of all these stud-
es is the dramatic decrease in early (day 100) TRM,
hich has ranged from 4% to 17%. This is even more
oteworthy in view of the fact some of these studies
ncluded a substantial number of patients who re-
entional Myeloablative Conditioning Regimens in Relapsed/Refractory
isease
ssion/Relapse PFS OS
Graft-vs-Hodgkin
Effect?
% (3 y) 15% (3 y) 21% (3 y) No
% (4 y) 15% (4 y) 25% (4 y) Possibly
% (4 y) 22% (5 y) 21% (5 y) Possibly
% (10 y) 26% (10 y) 30% (10 y) Possibly
% (5 y) 16% (4 y) 25% (4 y) Possibly
MT, European Group for Blood and Marrow Transplantation;
pkins Oncology Center; TRM, transplant-related mortality; PFS,
d donor and 3 from a matched unrelated donor.
ced Intensity Conditioning Regimens in Relapsed/Refractory Hodgkin
n TRM
Disease
Progression/
Relapse PFS OS
ly
g
17% (100-d)
24% (1-y)
27% (2-y)
48% (1-y)
64% (2-y)
26% (2-y) 46% (2-y;
projected)
- 4% (100-d)
16% (2-y)
43% 32% (4-y;
projected)
55% (4-y;
projected)
12% (100-d)
25% (1-y)
NA 32% (2-y) 48% (2-y)
n
5% (100-d)
22% (18-mo)
55% (18-mo) 32% (18-mo) 61% (18-mo)
11% (100-d)
39% (1-y)
47% (1-y) 18% (1-y) 51% (1-y)
n; UKCG, United Kingdom Collaborative Group; SPCP, Spanish
CRC, Fred Hutchinson Cancer Research Center; MRD, matched
e infusion; NA, not available; TRM, transplant-related mortality;th Conv
D
rogre
65
61
48
53
65
try; EB
hns Ho
d relateth Redu
egime
rimari
kylatin
lphalan
lphalan
ide;
elphala
e
antatio
ital; FH
ukocytradiation.
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RIC for Allo-SCT in HL
Beived transplants from a matched unrelated donor. It
hould be acknowledged that a decreased early TRM
s largely expected if the intensity of the conditioning
egimen is signiﬁcantly reduced. However, compared
ith patients who undergo allografting with myeloa-
lative regimens, even cumulative TRM has remained
elatively low thus far (15% to 30%). A longer follow-
p will be required to validate this conclusion.
Second, the willingness of investigators to include
n their studies sizable numbers of patients receiving
n allograft from a matched unrelated donor is impor-
ant. If RIC allo-SCT is to gain a role in the manage-
ent of these patients, the use of matched unrelated
onors is essential to expand the number of patients
ligible for the procedure. More stringent HLA-
yping and -matching criteria for donors have cer-
ainly helped. Although the issue has not been for-
ally examined, the outcome of these patients has not
een, in our experience, dramatically different thus far
rom that of patients who underwent matched and
elated donor allo-SCT (Anderlini P, unpublished
ata, 2005). Peggs et al [8] did not report statistically
igniﬁcant differences in overall and progression-free
urvivals in patients who underwent allografting from
atched related and unrelated donors.
Third, the incidence of disease progression/
elapse remains high, presumably because of the ad-
anced and refractory nature of the disease in these
atients. At least 2 studies have emphasized the role of
hemosensitivity before allo-SCT as a prognostic fac-
or [8,9], and it seems reasonable to make every effort
o cytoreduce these patients effectively before trans-
lantation. A double transplantation approach (auto-
CT followed by RIC allo-SCT) has been proposed as
n effective way to accomplish this goal [10].
Fourth, RIC regimens can be very heterogeneous.
ome are essentially devoid of any activity against the
alignancy (such as ﬂudarabine plus low-dose total
ody radiation) [11], whereas others have signiﬁcant
ctivity (such as ﬂudarabine plus melphalan) [8,12-14].
ne study [14] has suggested that the intensity of the
IC regimen has an effect on patient outcome, and this
rea should be explored further. If one accepts the con-
ept that a mounting an effective graft-versus-HL reac-
ion may require several months, preventing early pro-
ression in these patients becomes essential.
nterestingly, however, progression and relapse rates
ave been fairly consistent in all these studies
Table 2).
Fifth, at this time the data do not realistically help
n addressing the issue of the existence of a graft-
ersus-HL effect. It is unclear whether GVHD had
ny correlation with patient outcome. The issue may
e best approached from the donor leukocyte infusion
DLI) perspective, as described in more detail below.
Sixth, the jury is still out on what may be consid-
red the ultimate test, namely progression-free sur- (
B&MTival and overall survival. Only longer follow-up will
ventually answer the question. It should be pointed
ut that overall survival advantages can be hard to
emonstrate in HL clinical trials because of the effec-
iveness of salvage treatment [15,16]. A signiﬁcant
ecrease in TRM may be relevant in its own right
regardless of progression-free survival and overall
urvival) because more patients would survive the pro-
edure and would still be eligible to receive salvage
herapies (including DLIs) after allo-SCT.
OLE OF DLIS
DLIs remain in many ways a gold standard to
stablish the presence of a graft-versus-HL effect.
owever, published data on DLIs in HL are even
ketchier than those on RIC allo-SCT are. Porter et al
17] reported 4 cases of DLI after auto-SCT preceded
y interferon treatment in 3 of them, with 1 complete
esponse and 1 minor response. Peggs et al [8,12]
eported on 19 patients with HL (3 with preceding
alvage chemotherapy) from a cohort of 41 originally
ransplant recipients who received DLIs for residual
isease or disease progression (n  16) or mixed chi-
erism (n  3) after RIC allo-SCT. About 33% of
atients developed GVHD, and DLI-related mortal-
ty was 11%. The response rate was 9 of 16 (56%) of
valuable patients. Two of these responders had re-
eived prior chemotherapy, although none of the 5
aintained responses was in chemotherapy-treated
atients [8,12]. Although this response rate is high, the
nvestigators employed alemtuzumab-based condi-
ioning in all patients, which may have increased the
hance of response to the DLI. The frequent need for
LIs in this setting (characterized by profound B- and
-cell depletions in the infused graft) could be inter-
reted as indirect evidence in support of a graft-versus-
L effect. In the Spanish Prospective Cooperative Pro-
ocol, 11 patients received1 DLI for persistent disease
r disease progression [13]. In 3 cases the DLI was
receded by salvage chemotherapy. The response rate
as 54% (complete in 3 patients and partial in 3 pa-
ients). Acute GVHD developed in 5 patients (46%).
Our experience in this area was recently reported
18]. Nine patients with HL who had undergone allo-
CT received DLIs for treatment of persistent or
rogressive disease. Fifteen DLIs were performed,
ith 4 patients receiving 1 DLI. In 4 patients prior
alvage chemotherapy was administered. GVHD de-
eloped in all but 1 patient. The response rate was 4
f 9 (44%). Three of these 4 responders developed
VHD and 3 of 4 had received chemotherapy. No
orrelation was observed between CD3 cell dose
nfused and disease response. At the most recent
ollow-up, 3 patients were alive and 6 had expired
progressive disease, n  3; nonrelapse mortality, n 
601
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6). The median response duration was 7 months
range, 4-9), with 1 response currently ongoing.
As a whole, these limited data suggest that DLIs
or immunotherapy of recurrent HL have signiﬁcant
ctivity, although they frequently lead to GVHD.
hey clearly suggest, but do not prove, the existence
f a graft-versus-HL effect. The durability of the
esponses has been variable depending on the clinical
cenario, and the concomitant administration of che-
otherapy in many patients has interfered with inter-
retation of the data.
ONCLUSION
RIC allo-SCT in HL is generating a lot of inter-
st, but there are probably many more questions than
nswers at this stage. It should be recognized that this
s an intrinsically very challenging area because of the
ature of the patients involved and the refractoriness
f their disease. The results reported thus far are
learly appealing, and RIC allo-SCT is currently
eing given serious consideration in subsets of pa-
ients with HL (such as those with primary refrac-
ory disease), where outcome with conventional sal-
age treatments (including high-dose chemotherapy
nd autologous SCT) is known to be poor. Because
prospective comparative study between the myeloa-
lative and RIC approach is unlikely to occur, registry
ata should be reviewed in detail, and such an effort is
urrently ongoing (Anderlini P, Devetten M, personal
ommunication, 2005). More patients treated, better
atient selection, longer follow-up, and a more de-
ailed analysis of the data may better deﬁne the role of
IC allo-SCT in HL.
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